Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Catherine Dargan Named a “Most Influential Woman” in M&A

December 17, 2015

WASHINGTON, DC, December 17, 2015 - Mergers & Acquisitions magazine has named Catherine Dargan as one of “The Most Influential Women in Mid-Market M&A.” The inaugural special report celebrates 25 of “the best and the brightest female dealmakers.” Among a group of corporate executives and investment bankers, Ms. Dargan is the only outside counsel recognized.

Ms. Dargan, co-leader of the firm’s Mergers and Acquisitions practice, has broad experience in mergers and acquisitions, both public and private, and partnering arrangements. In addition to structuring and negotiating transactions, Ms. Dargan regularly assists clients with corporate governance, compliance and other matters, and advises on a variety of commercial agreements relating to manufacture, supply, and distribution of core products. Although Ms. Dargan has a particular expertise in the life sciences industry, her clients also include those in the defense and government contracting, consumer products, technology and gaming, media, sports, and equipment and manufacturing industries.

Mergers & Acquisitions highlighted Ms. Dargan’s cross-border transactional work for AstraZeneca, including its $600 million purchase of the U.S. and Canadian rights to Actavis’s branded respiratory business and its $325 million sale of assets and rights to Myalept to Aegerion Pharmaceuticals. The report also noted Ms. Dargan’s work on behalf Ben Venue Laboratories in its $300 million sale of Bedford Laboratories to Hikma Pharmaceuticals.

Share this article: